Cargando…

Protective autophagy decreases lorlatinib cytotoxicity through Foxo3a-dependent inhibition of apoptosis in NSCLC

Lorlatinib is a promising third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) that has been approved for treating ALK-positive non-small-cell lung cancer (NSCLC) patients with previous ALK-TKI treatment failures. However, the inevitable emergence of acquired resistance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Conghua, Yu, Rui, Zhang, Chong, Lin, Caiyu, Dou, Yuanyao, Wu, Di, Pan, Yonghong, Peng, Tao, Tang, Huan, Han, Rui, He, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033765/ https://www.ncbi.nlm.nih.gov/pubmed/35459209 http://dx.doi.org/10.1038/s41420-022-01027-z

Ejemplares similares

Aspirin sensitizes osimertinib‐resistant NSCLC cells in vitro and in vivo via Bim‐dependent apoptosis induction
por: Han, Rui, et al.
Publicado: (2020)

Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction
por: Chen, Hengyi, et al.
Publicado: (2017)

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date
por: Akamine, Takaki, et al.
Publicado: (2018)

pH-responsive theranostic nanoplatform of ferrite and ceria co-engineered nanoparticles for anti-inflammatory
por: Dou, Yuanyao, et al.
Publicado: (2022)

The potential therapeutic regimen for overcoming resistance to osimertinib due to rare mutations in NSCLC
por: Han, Rui, et al.
Publicado: (2023)

Lorlatinib-Induced Pulmonary Embolism in a Patient With an ALK-Positive NSCLC
por: Toyozawa, Ryo, et al.
Publicado: (2020)

Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC
por: Yun, Karen M, et al.
Publicado: (2022)

Alectinib and lorlatinib function by modulating EMT-related proteins and MMPs in NSCLC metastasis
por: Feng, Xu, et al.
Publicado: (2021)

Meningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib
por: Facchinetti, Francesco, et al.
Publicado: (2021)

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
por: Takeyasu, Yuki, et al.
Publicado: (2022)

First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN
por: Hayashi, Hidetoshi, et al.
Publicado: (2023)

Predictive value of early kinetics of ctDNA combined with cfDNA and serum CEA for EGFR‐TKI treatment in advanced non‐small cell lung cancer
por: Zheng, Jie, et al.
Publicado: (2022)

Lysophosphatidic acid exerts protective effects on HEI-OC1 cells against cytotoxicity of cisplatin by decreasing apoptosis, excessive autophagy, and accumulation of ROS
por: An, Xiaogang, et al.
Publicado: (2023)

Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution
por: Schneider, Jaime L., et al.
Publicado: (2023)

FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy
por: Guan, Shaoxing, et al.
Publicado: (2022)

Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
por: Hochmair, Maximilian J., et al.
Publicado: (2020)

Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
por: Liu, Geoffrey, et al.
Publicado: (2023)

Metformin Combining PD-1 Inhibitor Enhanced Anti-Tumor Efficacy in STK11 Mutant Lung Cancer Through AXIN-1-Dependent Inhibition of STING Ubiquitination
por: Wang, Zhiguo, et al.
Publicado: (2022)

The underlying mechanisms of lorlatinib penetration across the blood‐brain barrier and the distribution characteristics of lorlatinib in the brain
por: Chen, Wei, et al.
Publicado: (2020)

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report
por: Thummalapalli, Rohit, et al.
Publicado: (2023)

LZ-101, a novel derivative of danofloxacin, induces mitochondrial apoptosis by stabilizing FOXO3a via blocking autophagy flux in NSCLC cells
por: Guo, Yongjian, et al.
Publicado: (2019)

Overcoming Basal Autophagy, Kangai Injection Enhances Cisplatin Cytotoxicity by Regulating FOXO3a-Dependent Autophagic Cell Death and Apoptosis in Human Lung Adenocarcinoma A549/DDP Cells
por: Zhou, Huan, et al.
Publicado: (2022)

Exceptional response to lorlatinib and cabozantinib in ROS1-rearranged NSCLC with acquired F2004V and L2086F resistance
por: Sakamoto, Mandy, et al.
Publicado: (2023)

A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan
por: Goto, Yasushi, et al.
Publicado: (2023)

Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC
por: Ma, Xiya, et al.
Publicado: (2023)

Dihydromyricetin protects against liver ischemia/reperfusion induced apoptosis via activation of FOXO3a-mediated autophagy
por: Chen, Yongbiao, et al.
Publicado: (2016)

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases
por: Zhu, Viola W, et al.
Publicado: (2020)

Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report
por: Begum, Parvin, et al.
Publicado: (2022)

Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC
por: Zhou, Qing, et al.
Publicado: (2023)

Lorlatinib for non-small cell lung cancer
Publicado: (2020)

Evaluation and Management of Dyslipidemia in Patients Treated with Lorlatinib
por: Blais, Normand, et al.
Publicado: (2021)

Podcast on the Management of Adverse Events Associated with Lorlatinib
por: Bauer, Todd M., et al.
Publicado: (2022)

Esophageal Stricture Caused by ALK-Positive NSCLC Esophageal Metastasis Resolved After a Few Days of Lorlatinib Therapy Without Stent Placement
por: Longo, Vito, et al.
Publicado: (2020)

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
por: Mizuta, Hayato, et al.
Publicado: (2021)

Recent Advances in the Management of Adverse Events Associated with Lorlatinib
por: Liao, Dehua, et al.
Publicado: (2023)

Exercise-induced FNDC5/irisin protects nucleus pulposus cells against senescence and apoptosis by activating autophagy
por: Zhou, Wenxian, et al.
Publicado: (2022)

Down Regulation of SIRT2 Reduced ASS Induced NSCLC Apoptosis Through the Release of Autophagy Components via Exosomes
por: Wang, Lei, et al.
Publicado: (2020)

Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience
por: Rupp, Martin, et al.
Publicado: (2023)

BRD4 inhibition promotes TRAIL-induced apoptosis by suppressing the transcriptional activity of NF-κB in NSCLC
por: Shi, Liu, et al.
Publicado: (2021)

SGK1 inhibition induces autophagy-dependent apoptosis via the mTOR-Foxo3a pathway
por: Liu, Weiwei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_02i9foad3hmtirk2e10uaki657